Repository logo
 

Feasibility of Quantitative Magnetic Resonance Fingerprinting in Ovarian Tumors for T1 and T2 Mapping in a PET/MR Setting.

Accepted version
Peer-reviewed

No Thumbnail Available

Type

Article

Change log

Authors

Kaggie, Joshua D 
Kessler, Dimitri A 
McLean, Mary A 
Buonincontri, Guido 

Abstract

Multiparametric magnetic resonance imaging (MRI) can be used to characterize many cancer subtypes including ovarian cancer. Quantitative mapping of MRI relaxation values, such as T 1 and T 2 mapping, is promising for improving tumor assessment beyond conventional qualitative T 1- and T 2-weighted images. However, quantitative MRI relaxation mapping methods often involve long scan times due to sequentially measuring many parameters. Magnetic resonance fingerprinting (MRF) is a new method that enables fast quantitative MRI by exploiting the transient signals caused by the variation of pseudorandom sequence parameters. These transient signals are then matched to a simulated dictionary of T 1 and T 2 values to create quantitative maps. The ability of MRF to simultaneously measure multiple parameters, could represent a new approach to characterizing cancer and assessing treatment response. This feasibility study investigates MRF for simultaneous T 1, T 2, and relative proton density (rPD) mapping using ovarian cancer as a model system.

Description

Keywords

Cancer applications, clinical imaging, imaging techniques, magnetic resonance imaging (MRI), oncology, ovarian cancer

Journal Title

IEEE Trans Radiat Plasma Med Sci

Conference Name

Journal ISSN

2469-7311
2469-7311

Volume Title

3

Publisher

Institute of Electrical and Electronics Engineers (IEEE)
Sponsorship
Cancer Research Uk (None)
Cancer Research UK (CB4150)
Cancer Research UK (22905)
Cancer Research Uk (None)
Cancer Research UK (C12912/A27150)
The authors acknowledge research support from the National Institute of Health Research Cambridge Biomedical Research Centre, GlaxoSmithKline.Cancer Research UK (CRUK), the CRUK Cambridge Centre, Medical Research Council, CRUK/Engineering and Physical Sciences Research Council Imaging Centre in Cambridge and Manchester, Addenbrooke's Charitable Trust, and the Cambridge Experimental Cancer Medicine Centre.